Elevation goes down on Claudin disaster
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
SGO 2025 – Genmab’s advantage looks Profound
While Sutro shows why it’s shelved luvelta-T.
Otsuka bids for a seat at the conjugate table
The acquisition of Araris follows a 2023 discovery collaboration.
Sutro calls time on folate
At long last luvelta-T is shelved, and Sutro seeks a new focus.
ALX plays the conjugate card
Could a new ADC project distract attention away from evorpacept?
GSK and Hansoh press on despite Pfizer’s exit
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
